Cancer Research Technology
Log in Register
Menu

Anti-CD70, Recombinant [TAN 1-7]

Info

Catalogue Number 153278
Applications ELISA FACS IF Fn
Antigen/Gene or Protein Targets CD70
Synonyms CD70 Molecule; Tumor Necrosis Factor Ligand Superfamily Member 7; CD27 Ligand; CD27LG; TNFSF7; CD27L; Tumor Necrosis Factor Ligand 8A; Surface Antigen CD70; Ki-24 Antigen; CD70 Antigen; TNLG8A
Reactivity Mouse
Relevance Recombinant monoclonal antibody directed against CD70 cytokine, capable of blocking the CD70-CD27 interaction involved in B and T cell activation.

Background and Research Application
CD70 is a cytokine that belongs to the tumour necrosis factor (TNF) ligand family. This cytokine is a ligand for TNFRSF27/CD27. It is a surface antigen on activated, but not on resting, T and B lymphocytes and dendritic cells. It induces proliferation of co-stimulated T cells, enhances the generation of cytolytic T cells, and contributes to T cell activation. This cytokine is also reported to play a role in regulating B cell activation, cytotoxic function of natural killer cells, and immunoglobulin synthesis. CD70 expression is induced upon activation of DCs, indicating that the CD70-CD27 interaction could take place during the activation of naive T cells by DCs.
A recombinant version of anti-CD70, a non-depleting antibody which blocks the CD70-CD27 interaction. CD70 expression is thought to play a role in autoimmune disease regulation, and treatment of autoimmune diseases such as rheumatoid arthritis.
Host Rat
Immunogen Recombinant mouse CD70 (extracellular domain, aa residues 41-195)
Subclass IgG2a
Formulation PBS
Concentration 1mgml-1
Positive Control Activated dendritic cells
Research Area Immunology
Immunogen UniProt ID O55237
Notes Production Details
Purified using multi-step affinity chromatography with protein A.

Storage Conditions
Store at -20 degrees frozen. Avoid repeated freeze/thaw cycles.

Points of Interest
This antibody is a non-depleting mAb that blocks the CD70-CD27 interaction.
Recombinant monoclonal antibody produced from the original monoclonal cell line. Manufactured using Absolute Antibody’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma.
Suggested Dilutions: 1-10mg/ml

Five variants available:
- Anti-CD70 [TAN 1-7], Rat IgG2a, Kappa
- Anti-CD70 [TAN 1-7], Mouse IgG2a, Kappa
- Anti-CD70 [TAN 1-7], Mouse IgG2a, Kappa, engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors
- Anti-CD70 [TAN 1-7], Mouse IgG1-D265A, Fc Silenced, Kappa
- Anti-CD70 [TAN 1-7], Rabbit IgG, Kappa

Concentration
1mg/ml as standard

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Original hybridoma first published in: Rowley et al. 2004. J Immunol. 172(10):6039-46. PMID: 15128787.


Add a reference

References: 1 entry

Original hybridoma first published in: Rowley et al. 2004. J Immunol. 172(10):6039-46. PMID: 15128787.


Add a reference

Inventor Information